We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+24.62%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$306M
AUM Growth
+$1.8M
Cap. Flow
-$42.9M
Cap. Flow %
-14.03%
Top 10 Hldgs %
55.29%
Holding
87
New
18
Increased
13
Reduced
20
Closed
35

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$8.55M
2
ARGX icon
argenx
ARGX
+$5.82M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.76M
4
GPCR icon
Structure Therapeutics
GPCR
+$5.44M
5
ROIV icon
Roivant Sciences
ROIV
+$5.22M

Top Sells

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$12.9M
2
TGTX icon
TG Therapeutics
TGTX
+$8.72M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$7.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$7.44M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.48M

Sector Composition

Rank Sector Weight
1 Healthcare 56.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.63M 1.19%
225,000
-100,000
-31% -$1.28M
SVRA icon
27
Savara
SVRA
$1.13B
$3.52M 1.15%
+750,000
New +$2.87M
PHAT icon
28
Phathom Pharmaceuticals
PHAT
$873M
$3.52M 1.15%
385,241
-9,759
-2% -$84.1K
MDGL icon
29
Madrigal Pharmaceuticals
MDGL
$12.8B
$3.47M 1.13%
15,000
-42,500
-74% -$7.44M
CABA icon
30
Cabaletta Bio
CABA
$461M
$3.4M 1.11%
+150,000
New +$2.52M
REPL icon
31
Replimune Group
REPL
$859M
$3.37M 1.1%
+400,000
New +$4.64M
RVNC
32
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.3M 1.08%
375,000
+25,000
+7% +$205K
AMLX icon
33
CALL
Amylyx Pharmaceuticals
AMLX
$1.97B
$2.94M 0.96%
+200,000
New +$3.07M
PTGX icon
34
Protagonist Therapeutics
PTGX
$9.06B
$2.87M 0.94%
125,000
-275,000
-69% -$4.81M
ATXS
35
DELISTED
Astria Therapeutics
ATXS
$2.57M 0.84%
335,000
+35,000
+12% +$194K
ASND icon
36
Ascendis Pharma A/S
ASND
$17.1B
$2.52M 0.82%
20,000
-65,000
-76% -$6.48M
ARVN icon
37
Arvinas
ARVN
$517M
$2.44M 0.8%
+59,250
New +$1.39M
CRNX icon
38
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.31M 0.76%
65,000
-36,443
-36% -$1.12M
PMVP icon
39
PMV Pharmaceuticals
PMVP
$71.5M
$2.25M 0.73%
725,000
+19,119
+3% +$50.6K
NTRA icon
40
Natera
NTRA
$38.9B
$2.19M 0.72%
+35,000
New +$1.75M
RVMD icon
41
PUT
Revolution Medicines
RVMD
$39.6B
$2.15M 0.7%
+75,000
New +$1.8M
CBAY
42
DELISTED
Cymabay Therapeutics
CBAY
$2.13M 0.7%
+90,000
New +$1.6M
KALV
43
DELISTED
KalVista Pharmaceuticals
KALV
$1.59M 0.52%
130,036
+30,036
+30% +$273K
ACAD icon
44
Acadia Pharmaceuticals
ACAD
$4.38B
$1.57M 0.51%
50,000
-30,000
-38% -$716K
MRNS
45
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.47M 0.48%
+135,000
New +$1.01M
INBX
46
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.33M 0.43%
35,000
– –
COGT icon
47
Cogent Biosciences
COGT
$6.68B
$1.15M 0.37%
195,000
-455,000
-70% -$3.49M
QURE icon
48
uniQure
QURE
$2.77B
$1.12M 0.37%
165,000
-50,000
-23% -$330K
CYTK icon
49
Cytokinetics
CYTK
$10.9B
$835K 0.27%
10,000
-80,000
-89% -$2.9M
CATX icon
50
Perspective Therapeutics
CATX
$341M
$643K 0.21%
+160,000
New +$450K
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ghost Tree Capital held 87 positions worth $306M, up 0.59% from $304M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Ghost Tree Capital withdrew a net $42.9M in Q4 2023, closing 35 positions and reducing 20 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $7.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 68% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Biohaven worth $11.8M.

  • Ghost Tree Capital's largest Q4 2023 buy was Biohaven: 275,000 shares worth $11.8M.
  • Ghost Tree Capital added most to argenx in Q4 2023, an estimated $5.82M increase.
  • Ghost Tree Capital's biggest Q4 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $12.9M.
  • Ghost Tree Capital fully exited Alpine Immune Sciences Inc in Q4 2023, selling an estimated $7.6M.
  • Ghost Tree Capital's ten largest holdings make up 55% of its $306M portfolio in Q4 2023.
  • Ghost Tree Capital opened 18 new positions and closed 35 in Q4 2023.
  • Ghost Tree Capital's portfolio value rose 0.59% quarter-over-quarter to $306M.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.